The Patent Finder
IT

Intarcia Therapeutics, Inc.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Biomedicines, Inc. (to 2004)

27 patents currently held

5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
8 more records may belong here and await a decision; they are not counted.

The next term ends in Aug 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
11
Ending by 2030
Aug 2027
Next term end
15
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Composition and Dosage Form Comprising an Interferon Particle Formulation and Suspending Vehicle US 7,731,947
The most cited patent in this portfolio, cited by 145 later US patents, top 5% of utility patents granted in 2010 in our data. Protection runs to 2028.
Ends May 2028 · High confidence
Also notable
Devices, Formulations, and Methods for Delivery of Multiple Beneficial Agents US 8,926,595
Cited by 84 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2029.
Ends Sep 2029 · High confidence
Also notable
Solvent/Polymer Solutions as Suspension Vehicles US 8,114,437
Cited by 99 later US patents, top 10% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.
Ends Aug 2027 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 23, 2026
    The maintenance fee for Methods Comprising Continuous Administration of Exenatide and Co-Administration of a Drug (US 11,654,183) comes due Nov 23, 2026. Unpaid by May 24, 2027, it lapses early.
  • 1 fee due Feb 28, 2027
    The maintenance fee for Long Acting Peptide Tyrosine Tyrosine (PYY) Analogs and Methods of Use (US 11,739,134) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
  • 1 fee due Apr 15, 2027
    The maintenance fee for Devices, Formulations, and Methods for Delivery of Multiple Beneficial Agents (US 10,441,528) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
  • 1 fee due Jun 10, 2027
    The maintenance fee for Glucagon-Receptor Selective Polypeptides and Methods of Use Thereof (US 10,501,517) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
  • 1 fee due Jul 7, 2027
    The maintenance fee for Osmotic Delivery Systems and Piston Assemblies for Use Therein (US 10,527,170) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
  • 1 fee due Sep 10, 2027
    The maintenance fee for THERAPEUTIC METHODS FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS FOR PATIENTS WITH HIGH BASELINE HbA1c (US 10,583,080) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 7,682,356Osmotic Delivery Systems and Piston Assemblies for Use Therein
In force
 · High confidence
In forceHigh confidence
US 7,879,028Osmotic Delivery Systems and Piston Assemblies for Use Therein
In force
 · High confidence
In forceHigh confidence
US 8,114,437Solvent/Polymer Solutions as Suspension Vehicles
In force
 · High confidence
In forceHigh confidence
US 7,731,947Composition and Dosage Form Comprising an Interferon Particle Formulation and Suspending Vehicle
In force
 · High confidence
In forceHigh confidence
US 7,959,938Polyoxaester Suspending Vehicles for Use with Implantable Delivery Systems
In force
 · High confidence
In forceHigh confidence
US 8,940,316An osmotic delivery device comprising an insulinotropic peptide and uses thereof
In force
 · Medium confidence
In forceMedium confidence
US 10,527,170Osmotic Delivery Systems and Piston Assemblies for Use Therein
In force
 · High confidence
In forceHigh confidence
US 8,052,996Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator
In force
 · Medium confidence
In forceMedium confidence
US 10,441,528Devices, Formulations, and Methods for Delivery of Multiple Beneficial Agents
In force
 · Medium confidence
In forceMedium confidence
US 8,926,595Devices, Formulations, and Methods for Delivery of Multiple Beneficial Agents
In force
 · High confidence
In forceHigh confidence
10 of 27 patents shown.
Pro members see all 27.
Pro members: see all 27 patents
Also on record, not counted in the 27: 5 patents in force now held by others · 56 patents ended · 44 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited